Patents Assigned to Eisai R&D Management Co., Ltd.
  • ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
    Publication number: 20250092392
    Abstract: Novel antisense oligonucleotides that induce Exon-2 skipping in the CD33 gene during pre-mRNA splicing, and their use in the treatment of a neurodegenerative disease, such as Alzheimer's disease, are disclosed.
    Type: Application
    Filed: April 28, 2022
    Publication date: March 20, 2025
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Vinod VATHIPADIEKAL, Branko MITASEV, Courtney EASLEY-NEAL, Hyeong Wook CHOI, Francis G. FANG, John WANG, Praveen VEMULA, Jung Hwa LEE
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 12251386
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: September 29, 2022
    Date of Patent: March 18, 2025
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Methods for the treatment of bladder cancer
    Patent number: 12251394
    Abstract: Provided herein are methods for the treatment of bladder cancer.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 18, 2025
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-Wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Fluorescent dye and use thereof
    Patent number: 12253526
    Abstract: Disclosed is: a fluorescent dye comprising a compound, a tautomer of the compound, or a salt of the compound or the tautomer; a labeled composite substance comprising the fluorescent dye and a composite substance which are bonded to each other; a composition containing the fluorescent dye or the labeled composite substance; and a method for acquiring information about a substance of interest by a super-resolution microscopy.
    Type: Grant
    Filed: February 1, 2021
    Date of Patent: March 18, 2025
    Assignees: Eisai R&D Management Co., Ltd., SYSMEX CORPORATION
    Inventors: Daiki Hara, Takafumi Motoki, Yuji Kazuta, Yoshihiko Norimine, Hiroyuki Amino, Masatoshi Suganuma, Shingo Fujiyama, Kazuto Yamashita, Masaya Okada, Yoichi Nishikawa, Shigeki Iwanaga
  • METHODS OF TREATING IRREGULAR SLEEP-WAKE RHYTHM DISORDER AND CIRCADIAN RHYTHM SLEEP DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES
    Publication number: 20250064802
    Abstract: Methods of treating sleep-wake rhythm disorder and related circadian rhythm sleep disorders associated with neurodegenerative diseases are disclosed.
    Type: Application
    Filed: July 20, 2022
    Publication date: February 27, 2025
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Margaret L MOLINE, Jocelyn Y CHENG, Jane YARDLEY
  • Treatment of hepatocellular carcinoma
    Patent number: 12226409
    Abstract: This disclosure provides methods for treating a hepatocellular carcinoma (e.g., unresectable HCC) with lenvatinib or a pharmaceutically acceptable salt thereof. Also encompassed by the disclosure are dosage regimens described herein of lenvatinib or a pharmaceutically acceptable salt thereof for use in treating hepatocellular carcinoma (e.g., unresectable hepatocellular carcinoma) according to any of the methods described herein. Particularly useful dosages and dose modifications upon the occurrence of an adverse event or events are also disclosed.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: February 18, 2025
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Toshiyuki Tamai
  • CRYSTALLINE SALT FORM OF EP4 ANTAGONIST
    Publication number: 20250051285
    Abstract: A crystalline free acid form of (S)-4-(1-(3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazole-4-carboxamido)ethyl)benzoic acid is provided. Methods of making and using the crystalline free acid form of (S)-4-(1-(3-(difluoromethyl)-1-methyl-5-(3-(trifluoromethyl)phenoxy)-1H-pyrazole-4-carboxamido)ethyl)benzoic acid are also provided.
    Type: Application
    Filed: December 22, 2022
    Publication date: February 13, 2025
    Applicant: Eisai R&D Management Co., Ltd.
    Inventor: Farid Benayoud
  • Tumor therapeutic agent
    Patent number: 12220398
    Abstract: A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: February 11, 2025
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Kiyoshi Okamoto, Junji Matsui, Corina Dutcus
  • C-terminal lysine conjugated immunoglobulins
    Patent number: 12214050
    Abstract: Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.
    Type: Grant
    Filed: August 20, 2021
    Date of Patent: February 4, 2025
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Jared Spidel, Earl Albone
  • Splicing modulator antibody-drug conjugates and methods of use
    Patent number: 12172986
    Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: December 24, 2024
    Assignee: EISAI R&D MANAGEMENT CO., LTD
    Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
  • Method for treating cancer
    Patent number: 12168014
    Abstract: The present invention relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s).
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: December 17, 2024
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Heike Keilhack, Brett Truitt, Yuta Suzuki, Tsukasa Murase, Futoshi Shikata
  • CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE
    Publication number: 20240368140
    Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
    Type: Application
    Filed: February 20, 2024
    Publication date: November 7, 2024
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Gregg F. KEANEY, John WANG, Baudouin GERARD, Kenzo ARAI, Xiang LIU, Guo Zhu ZHENG, Kazunobu KIRA, Lisa A. MARCAURELLE, Marta NEVALAINEN, Ming-Hong HAO, Morgan Welzel O'SHEA, Parcharee TIVITMAHAISOON, Sudeep PRAJAPATI, Tuoping LUO, Nicholas C. GEARHART, Jason T. LOWE, Yoshihiko KOTAKE, Satoshi NAGAO, Regina Mikie KANADA SONOBE, Masayuki MIYANO, Norio MURAI, Andrew COOK, Shelby ELLERY, Atsushi ENDO, James PALACINO, Dominic REYNOLDS
  • MACROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20240309014
    Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
    Type: Application
    Filed: October 4, 2023
    Publication date: September 19, 2024
    Applicants: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
    Patent number: 12083112
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: September 10, 2024
    Assignees: EISAI R&D MANAGEMENT CO., LTD., Merck Sharp & Dohme LLC
    Inventors: Andrew Evan Denker, Yu Kato, Kimiyo Tabata, Yusaku Hori
  • Liposome composition
    Patent number: 12042560
    Abstract: The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: July 23, 2024
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Hiroshi Kikuchi, Kenji Hyodo, Hiroshi Ishihara
  • Anti-BCMA antibody-drug conjugates and methods of use
    Patent number: 12043670
    Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: July 23, 2024
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryan Henry, Thiwanka Samarakoon, Nathan Fishkin, Ping Zhu, Ermira Pazolli, James Palacino, Juan C. Almagro
  • Pharmaceutical composition for treating tumor
    Patent number: 12036204
    Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
    Type: Grant
    Filed: December 28, 2021
    Date of Patent: July 16, 2024
    Assignees: EISAI R&D MANAGEMENT CO., LTD., ONO PHARMACEUTICAL CO., LTD.
    Inventors: Taro Semba, Yasuhiro Funahashi, Takuya Suzuki
  • Method for inhibiting tumor growth
    Patent number: 12029724
    Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: July 9, 2024
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Makoto Asano, Junji Matsui
  • Health condition monitoring set
    Patent number: D1032850
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: June 25, 2024
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Rajeev Narayanan, David Levin, Alexander Scott
  • Charging unit for a health condition monitoring system
    Patent number: D1066682
    Type: Grant
    Filed: May 17, 2024
    Date of Patent: March 11, 2025
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Rajeev Narayanan, David Levin, Alexander Scott